June 7, 2012
Astellas Pharma announced on June 5 the initiation of a PIIb dose finding study in the US and Europe for quizartinib (development code: AC220), an investigational treatment for relapsed and refractory acute myeloid leukemia (AML) developed jointly with Ambit Biosciences...read more